XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
In connection with the planned Separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation. As a result, during the first quarter of 2021, the Company’s Chief Executive Officer ("CEO"), who is the Company’s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company's historical segment structure. This realignment is consistent with how the Company’s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2021, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. In addition, as part of this realignment of segment structure, certain products historically included in certain segments are now included in their new respective segments based on the organizational structure of the two separate entities as proposed by the Separation. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.
The following is a brief description of the Company’s segments:
•The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products.
•The Salix segment consists of sales in the U.S. of GI products.
•The International Rx segment consists of sales, with the exception of sales of Bausch + Lomb and Solta products, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
•The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
•The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration and separation costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
Segment Revenues and Profits
Segment revenues and profits for the three months ended March 31, 2021 and 2020 were as follows:
Three Months Ended March 31,
(in millions)20212020
Revenues:
Bausch + Lomb$881 $875 
Salix472 477 
International Rx306 291 
Ortho Dermatologics141 131 
Diversified Products227 238 
$2,027 $2,012 
Segment profits:
Bausch + Lomb$239 $263 
Salix327 319 
International Rx109 98 
Ortho Dermatologics70 47 
Diversified Products171 167 
916 894 
Corporate(181)(156)
Amortization of intangible assets(357)(436)
Goodwill impairments(469)— 
Asset impairments(148)(14)
Restructuring, integration and separation costs(12)(4)
Other income (expense), net30 (36)
Operating (loss) income(221)248 
Interest income2 7 
Interest expense(368)(396)
Loss on extinguishment of debt(5)(24)
Foreign exchange and other1 (13)
Loss before (provision for) benefit from income taxes$(591)$(178)
Revenues by Segment and Product Category
Revenues by segment and product category were as follows:
Three Months Ended March 31, 2021
(in millions)Bausch + LombSalixInternational RxOrtho DermatologicsDiversified ProductsTotal
Pharmaceuticals$125 $470 $59 $65 $177 $896 
Devices382 — — 72 — 454 
OTC316 — 25 — 2 343 
Branded and Other Generics 51 — 212 — 47 310 
Other revenues7 2 10 4 1 24 
$881 $472 $306 $141 $227 $2,027 

Three Months Ended March 31, 2020
(in millions)Bausch + LombSalixInternational RxOrtho DermatologicsDiversified ProductsTotal
Pharmaceuticals$138 $477 $66 $76 $182 $939 
Devices341 — — 51 — 392 
OTC321 — 26 — 2 349 
Branded and Other Generics68 — 188 — 50 306 
Other revenues7 — 11 4 4 26 
$875 $477 $291 $131 $238 $2,012 
The top ten products for the three months ended March 31, 2021 and 2020 represented 40% and 40% of total revenues for the three months ended March 31, 2021 and 2020, respectively.
Geographic Information
Revenues are attributed to a geographic region based on the location of the customer and were as follows:
Three Months Ended March 31,
(in millions)20212020
U.S. and Puerto Rico$1,162 $1,211 
China110 58 
Canada76 90 
Mexico69 41 
Egypt66 58 
Poland62 73 
Japan60 54 
France54 47 
Germany42 44 
Russia31 34 
United Kingdom25 23 
South Korea20 17 
Other250 262 
$2,027 $2,012 
Major Customers
Customers that accounted for 10% or more of total revenues were as follows:
Three Months Ended March 31,
20212020
AmerisourceBergen Corporation18%19%
McKesson Corporation (including McKesson Specialty)16%16%
Cardinal Health, Inc.12%13%